Atty Dkt. No.: BERK-017CIP USSN: 10/547.999

AMENDMENTS

In the Claims:

Claims 1-13. (Cancelled)

14. (Currently Amended) A method of eliciting or boosting a cellular immune response to an antigen in a subject, said method comprising:

administering to said subject an effective amount of Listeria cells, wherein said cells are transformed with an integration vector capable of site-specific Listeria genome integration according to Claim-13.

- (Original) The method according to Claim 14, wherein said Listeria cells are attenuated.
- (Withdrawn) A vaccine comprising a strain of Listeria cells according to Claim
 wherein said Listeria cells express a heterologous antigen.
- 17. (Withdrawn) The vaccine according to Claim 16, wherein said Listeria cells are attenuated.
- 18. (Withdrawn) A recombinant culture of Listeria cells according to Claim 13.
- (Withdrawn) The recombinant culture according to Claim 18, wherein said Listeria cells are attenuated.
- 20. (Withdrawn) A kit for use in preparing a vector according to Claim 7, said kit comprising:
 - a vector according to Claim 1; and at least one nuclease that cuts said vector at said multiple cloning site.

Atty Dkt. No.: BERK-017CIP USSN: 10/547,999

21. (Withdrawn) The kit according to Claim 20, wherein said kit further comprises a host cell.

22. (Withdrawn) A kit for use in preparing a cell according to Claim 13, said kit comprising:

a vector according to Claim 1;

at least one nuclease that cuts said vector at said multiple cloning site; and a Listeria cell.

24. (Withdrawn) A system for preparing a vaccine according to Claim 16, said system comprising:

a vector according to Claim 1;

at least one nuclease that cuts said vector at said multiple cloning site;

a coding sequence for said heterologous antigen;

and

Listeria cells.

Please enter the following new claims:

 (New) The method according to Claim 14, wherein said integration vector is a plasmid.

- (New) The method according to Claim 25, wherein said integration vector comprises a bacteriophage integrase gene and a bacteriophage attachment site.
- 27. (New) The method according to Claim 26, wherein said bacteriophage is a listeriophage.
- 28. (New) The imethod according to Claim 26, wherein said attachment site provides for integration at an integration site selected from the group consisting of: the comK

Atty Dkt. No.: BERK-017CIP USSN: 10/547,999

integration site and the tRNAArg integration site.

- (New) The method according to Claim 14, wherein said integration vector further includes a multiple cloning site.
- 30. (New) The method according to Claim 29, wherein said integration vector further includes a coding sequence.
- 31. (New) The method according to Claim 30, wherein said coding sequence encodes a polypeptide.
- 32. (New) The method according to Claim 31, wherein said polypeptide is an antigen.
- 33. (New) The method according to Claim 14, wherein said integration vector is pPL1.
- 34. (New) The method according to Claim 14, wherein said integration vector is pPL2.